YiSheng Biotechnology (01061) issues a profit warning, expecting a decrease of approximately 30% in mid-term profits compared to the same period last year.

Wisdom Financial News APP, Yi Sheng Biotechnology (01061) announced that the Group expects that for the six months ending on June 30, 2026 (the mid-year period of 2026), the Group's revenue and profit will decrease by about 10% and 30% respectively compared to the same period in 2025, with revenue approximately HK $877 million and profit approximately HK $163 million. This is mainly due to the increase in value-added tax borne by the Group after the implementation of the new value-added tax law in China.